Hyderabad company develops India’s first DCGI-approved vaccine candidate, gets nod for human trials

Credit: IndiaTimes- Published on June 29, 2020

You are here


💡 newsR Knowledge: Other News Mentions

Hyderabad

Capital of Telangana, India
The trucks, belonging to the private container freight station are moving to a Hyderabad-based company that had bid for the chemicals.
Credit: DNA - Published 2 days ago

Customs have moved 10 containers with 181 tonnes of ammonium nitrate from the Manali Sattva Container Freight Station (CFS) on Sunday evening to a..
Credit: IndiaTimes - Published 2 days ago


Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use on COVID-19 patients as a potential treatment
Credit: DNA - Published 1 week ago

India’s apex drug regulator has allowed Pune-based Serum Institute of India to conduct late-stage — Phase 2 and 3 — human trials in India for the Oxford..
Credit: IndiaTimes - Published 1 week ago

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India for conducting phase 2 and 3 human clinical trials of the Oxford..
Credit: IndiaTimes - Published 1 week ago


Related videos from verified sources

Moderna vaccine protects monkeys, next: 30,000 humans on trial | Oneindia News 02:53
Credit: Oneindia - Published 2 weeks ago 


Covid: First part of phase-1 Covaxin human trial completed at PGI Rohtak 02:37
Credit: HT Digital Content - Published 2 weeks ago 


Covid vaccine: India begins testing indigenous candidate at PGIMS, Rohtak 02:50
Credit: HT Digital Content - Published on July 18, 2020 


Related news from verified sources

India’s first Covid-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the National Institute of Virology (NIV),...
on June 30, 2020 • IndiaTimes

You might like